Resverlogix Corp. Company Profile | StatInvestor

Health Care & Life Sciences » Biotechnology | Resverlogix Corp.

Resverlogix Corp.

Resverlogix Corp.
Stock Exchange	Other OTC
EPS	$0.61
Market Cap	$466.63 M
Shares Outstanding	177.43 M
Public Float	-

Resverlogix Corp.
Stock Exchange	Toronto Stock Exchange Prices
EPS	CAD0.8
Market Cap	CAD608.3 M
Shares Outstanding	204.15 M
Public Float	107.4 M

Profile

Address	4820 Richard Road SW Calgary Alberta T3E 6L1 Canada
Employees	-
Website	http://www.resverlogix.com
Updated	07/08/2019
Resverlogix Corp. is a clinical stage biotechnology company, which engages in the research and development of pharmaceutical products for cardiovascular diseases. It develops Apabetalone for diabetes mellitus, chronic kidney, peripheral artery, Orphan and Alzheimer's diseases. The company was founded by Donald J.

Financials

Donald J. McCaffrey

Chairman, President, CEO & Secretary

Norma K. Biln

Independent Director